EIF4EBP1 and cancer: Rapalink-1 is more potent than first- and second- generation mTOR inhibitors in reducing the levels of both p-4EBP1 and cell proliferation; as a consequence, RapaLink-1 led to regression of tumor xenografts models and could durably block mTORC1; moreover, it showed better efficacy than rapamycin or mTOR kinase inhibitors, potently blocking cancer-derived, activating mutants of mTOR.